King Altace sNDA Submitted For Five Indications; 4th Quarter Sales Grew 46%

King submitted an Altace (ramipril) sNDA Jan. 18 for the significant reduction of mortality, myocardial infarction, stroke, revascularization procedures and heart failure in patients at risk for such events.